- Home
- WST vs EQR Comparison
WST vs EQR Comparison
Compare WST & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WST | EQR |
|---|---|---|
| Founded | 1923 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9B | 24.3B |
| IPO Year | 2004 | 1994 |
Fundamental Metrics
Financial Performance| Metric | WST | EQR |
|---|---|---|
| Price | $243.38 | $58.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $319.43 | $69.42 |
| AVG Volume (30 Days) | 718.9K | ★ 2.0M |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | 0.37% | ★ 4.78% |
| EPS Growth | 1.49 | ★ 8.09 |
| EPS | ★ 6.79 | 2.94 |
| Revenue | ★ $2,886,900,000.00 | $2,701,075,000.00 |
| Revenue This Year | $6.73 | $4.33 |
| Revenue Next Year | $6.07 | $3.07 |
| P/E Ratio | $34.94 | ★ $19.76 |
| Revenue Growth | 1.95 | ★ 4.76 |
| 52 Week Low | $187.43 | $57.57 |
| 52 Week High | $322.34 | $72.65 |
Technical Indicators
Market Signals| Indicator | WST | EQR |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 35.56 |
| Support Level | $241.57 | N/A |
| Resistance Level | $251.73 | $64.20 |
| Average True Range (ATR) | 6.76 | 1.20 |
| MACD | 0.26 | -0.35 |
| Stochastic Oscillator | 53.16 | 18.89 |
Price Performance
Historical ComparisonAbout WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 318 apartment communities with over 86,000 units and is developing three additional properties with 935 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.